Emoxibel - instructions for use, dose, side effects, contraindications

Emoxibel has a beneficial effect on the blood clotting system: inhibits the aggregation of platelets, reduces the overall coagulation index, prolongs the clotting time. Stabilizes the membranes of cells of blood vessels and erythrocytes, increases the resistance of red blood cells to mechanical trauma and hemolysis. It has angioprotective properties. Improves microcirculation. Effectively inhibits free radical oxidation of lipids of biomembranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has an antitoxic effect. In extreme situations, accompanied by increased lipid peroxidation and hypoxia, it optimizes bioenergetic processes. Increases brain resistance to hypoxia and ischemia. In cases of cerebrovascular disorders (ischemic and hemorrhagic) contributes tocorrection vegetative dysfunction, facilitates the restoration of integrative activities brain, improves mnestic functions. Has hypolipidemic action, reduces the synthesis of triglycerides. Expands coronary vessels, reduces ischemic injury of the myocardium. With myocardial infarction limits the magnitude of the focus of necrosis, accelerates reparative processes, promotes normalization of myocardial metabolism. Has a beneficial effect on clinical course of myocardial infarction, reducing the incidence of acute heart failure. Promotes the regulation of oxidation- restoration system in case of circulatory failure.

Pharmacokinetics:

When administered intravenously at a dose of 10 mg / kg, a low semi-elimination period (T1/2 - 18 min, which indicates a high speed elimination of the drug from the blood). The value of the elimination constant is 0.041 min; total ground clearance FROM₁-214.8 ml / min; apparent volume of distribution V_each. - 5.2 liters. The drug quickly penetrates into the organs and tissues, where it is deposited and metabolism. There were 5 metabolites of emoxibel, dealkylated and conjugated products of its transformation. Metabolites emoksibela excreted by the kidneys. In significant quantities in liver, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found. In pathological conditions, for example, in the case of coronary occlusion, the pharmacokinetics of the emoxibel are changing. Reduces the rate of excretion, as a result of which the bioavailability of the drug increases. Time increases finding emoxibel in the bloodstream, which may be due to its return receipt from depot, including from ischemic myocardium.

Indications:

In Neurology and Neurosurgery: hemorrhagic stroke, ischemic stroke in the internal carotid artery and vertebrobasilar system, transient cerebral blood flow disorders, chronic cerebral circulatory insufficiency, craniocerebral trauma accompanied by brain contusions; postoperative period in patients with craniocerebral trauma, operated on the epidural, subdural and intracerebral hematomas, combined with bruises of the brain.

In cardiology: acute myocardial infarction, prevention of "reperfusion syndrome", unstable angina.

Contraindications:

Increased individual sensitivity to emoxibel, pregnancy, lactation, children under 18 years.

Pregnancy and lactation:Contraindicated.

Dosing and Administration:

In Neurology and Neurosurgery emoksibel used intravenously drip in a daily dose of 5 - 10 mg / kg for 10 - 12 days. Enter at a speed of 20 - 30 drops per minute. Subsequently, 2 to 10 ml of a 30 mg / ml solution (60 to 300 mg) 2-3 times daily for intramuscular injection 10-30 days.

In cardiology begin with an intravenous drip (20 - 40 drops per minute) administration of 120-180 ml (600-900 mg) 1-3 times a day for 5-15 days depending on the course of the disease, in the future they switch to intramuscular injection of 2-10 ml of the drug at a concentration of 30 mg / ml (60-300 mg) 2 to 3 times a day for 10-30 days.

Treatment with emoxibel should be carried out under the control of blood pressure and the functional state of coagulating and anticoagulating blood systems.

Side effects:

at intravenous introduction - sensation of a burning sensation on a course of a vein;
increased blood pressure, excitation (short-term), or drowsiness;
headache, pain in the heart;
nausea, discomfort in the epigastric region;
itching and redness of the skin;
allergic reactions.

Overdose:

In case of an overdose, there may be an increase in the side effects of the drug (the onset of drowsiness and sedation), a brief increase in blood pressure.

Treatment: symptomatic, including the appointment of antihypertensive drugs under the control of blood pressure. There is no specific antidote.

Interaction:

α -Tocopherol acetate potentiates the antioxidant effect of emoxibel.

Special instructions:

At the beginning of treatment with the drug, it is advisable to refrain from engaging in potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

It is necessary during the treatment to constantly monitor blood pressure and clotting of blood.

Emoxibel solution for infusion is not recommended to be mixed with other drugs.

Form release / dosage:

Solution for infusions 5 mg / ml.

Packaging:

100 ml in bottles of glass, corked with rubber stoppers and crimped with aluminum caps. Each bottle, along with instructions for use, is placed in a cardboard package.

56 bottles together with an equal number of instructions for use in corrugated cardboard boxes.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-009112/10

Date of registration:31.08.2010

Manufacturer: & nbsp

BELMEDPREPARATY, RUP Republic of Belarus

Representation: & nbsp"Belmedpreparaty" RUP "Belmedpreparaty" RUP

Information update date: & nbsp10.06.2015

Illustrated instructions

Instructions

Emoxibel (Emoxibel)